Recent Company News

• 07:35 AM ET Oct 30, 2025
  

  StreetAccount Summary - European unusual volume traders

• 02:05 AM ET Dec 18, 2025
  

  PureTech Health appoints interim CEO Robert Lyne as CEO, effective immediately (121.0000p, 0)

• 04:21 AM ET Dec 08, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:06 AM ET Dec 08, 2025
  

  PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis (122.0000p, 0)

• 01:07 PM ET Dec 05, 2025
  

  PureTech Health's Gallop Oncology reports Phase 1B trial results for LYT-200 (122.0000p, 0)

• 07:02 AM ET Dec 03, 2025
  

  Bristol Myers Squibb announces continuation of ADEPT-2 Phase 3 study in psychosis associated with Alzheimer's Disease ($48.25, 0.00)

• 02:18 AM ET Oct 22, 2025
  

  PureTech Health presents new Phase 2b analyses demonstrating consistent safety and efficacy of deupirfenidone in older patients with IPF (133.4000p, 0)